2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

Confirm Password

About Us
Team
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos

December 11, 2020

0 Comments

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

2021 ASCO Virtual Direct™ Highlights San Francisco

Sat, Jul 31, 2021

05:09

Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples

14:15

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin

23:44

UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby

26:18

Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

08:15

2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein

12:53

2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli

25:51

KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah

05:33

Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne

13:23

Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

17:44

UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytokine Re…

Feat. S. Kosuri

05:11

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Rel…

Feat. B. Derman

26:48

Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

22:47

UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussion…

Feat. M. Leukam

23:48

UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Resul…

Feat. J. Jasielec

09:00

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among the My…

Feat. J. Berdeja

12:16

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos

09:50

Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

12:03

Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

06:21

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in Im…

Feat. F. Anwer

06:12

Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Firs…

Feat. K. Anderson

Login

Login

Join VuMedi

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

Related Content